Heart failure & cardiomyopathies
Aficamten Treatment for Symptomatic Obstructive Hypertrophic Cardiomyopathy: 48-Week Results From FOREST-HCM
Authors' conclusion
Aficamten treatment over 48 weeks was well tolerated and associated with substantial and durable relief of obstruction and symptom burden, lower cardiac biomarker levels, and cardiac phenotypic changes, which may indicate favorable cardiac remodeling.
Study context
- Population
- Participants with symptomatic obstructive hypertrophic cardiomyopathy from REDWOOD-HCM or SEQUOIA-HCM46 with 48 weeks evaluated
- Participants
- 213 participants
- Outcome
- LV outflow tract gradient, change from baseline
- Follow-up
- Week 48
Methodological detailsphase 2/3, ongoing, Enrolment May 2021 to October 2023
- Phase 2/3
- Ongoing
- Enrolment May 2021 to October 2023
Main finding
As reported in the abstract
Mean resting LV outflow tract gradient change
−40 ± 34 mm Hg
Valsalva peak LV outflow tract gradient change
−53 ± 39 mm Hg
Further findings
Symptoms
- ≥1 NYHA class improvement
- 82%
- 20-point improvement in KCCQ-Clinical Summary score
- 31%
Cardiac structure and biomarkers (mean change)
- Maximum LV wall thickness
- −1.2 ± 1.6 mm; P < 0.0001
- Left atrial volume index
- −3.5 ± 6.6 mL/m²; P = 0.0008
- Lateral E/e'
- −2.2 ± 6.1; P = 0.02
- Cardiac biomarkers
- P ≤ 0.0031
Safety
Safety and tolerability · 48 weeks
- Asymptomatic, transient LVEF <50% (range 47%-49%), neither resulting in drug discontinuation
- 2 (4.3%)
- No new-onset AF
Original publication
Aficamten Treatment for Symptomatic Obstructive Hypertrophic Cardiomyopathy: 48-Week Results From FOREST-HCM. JACC Heart Fail. Published 19 June 2025. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →